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ABSTRACT: Autism spectrum disorder (ASD) is a neurodevelopmental
disorder with no clinical biomarker. The aims of this study were to
characterize a metabolic signature of ASD and to evaluate multiplatform
analytical methodologies in order to develop predictive tools for
diagnosis and disease follow-up. Urine samples were analyzed using 1H
and 1H−13C NMR-based approaches and LC−HRMS-based approaches
(ESI+ and ESI− on HILIC and C18 chromatography columns). Data
tables obtained from the six analytical modalities on a training set of 46
urine samples (22 autistic children and 24 controls) were processed by
multivariate analysis (orthogonal partial least-squares discriminant
analysis, OPLS-DA). The predictions from each of these OPLS-DA
models were then evaluated using a prediction set of 16 samples (8
autistic children and 8 controls) and receiver operating characteristic
curves. Thereafter, a data fusion block-scaling OPLS-DA model was
generated from the 6 best models obtained for each modality. This fused OPLS-DA model showed an enhanced performance
(R2Y(cum) = 0.88, Q2(cum) = 0.75) compared to each analytical modality model, as well as a better predictive capacity (AUC =
0.91, p-value = 0.006). Metabolites that are most signiﬁcantly diﬀerent between autistic and control children (p < 0.05) are
indoxyl sulfate, N-α-acetyl-L-arginine, methyl guanidine, and phenylacetylglutamine. This multimodality approach has the
potential to contribute to ﬁnd robust biomarkers and characterize a metabolic phenotype of the ASD population.
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■ INTRODUCTION
Autism spectrum disorder (ASD) refers to a group of complex
neurodevelopmental disorders present since early childhood
and persisting lifelong.1 The prevalence of ASD was recently
estimated in France to 36.5/10 000 children with a sex ratio of
4.1 boys for 1 girl.2
Autism is typically diagnosed before 3 years of age,3 and ASD
children are characterized by deﬁcits in social communication
and social interaction, as well as restricted and repetitive
behaviors and interests, as listed in the American Psychiatric
Association’s Diagnostic and Statistical Manual of Mental
Disorders, 5th ed. (DSM-V).4 Diagnosis is made clinically by
using diﬀerent scale tests that evaluate the behavior of the
patient,5 and to date, there is no reliable biochemical marker of
this disorder. Although etiologies of autism remain unknown,
studies have found implications of genetic, environmental, and
metabolic factors.6 ASD has several suspected causes, including
dysfunctions of the neurologic, immunologic, and/or gastro-
intestinal systems, with some markers showing ubiquitous
distribution. Due to the social and communication impairments
of patients with ASD, identifying gastrointestinal problems
remains diﬃcult. However, some studies have linked an
imbalance of the gut microbiota with ASD.7
Some metabolic disorders have been found to be more
frequent in the autistic population compared to the general
population. These abnormalities include phenylketonuria,
creatine deﬁciency syndromes, adenylosuccinate lyase deﬁ-
ciency, 5-nucleotidase, and metabolism of purine pyrimidine
disorders. The metabolic abnormalities that contribute to the
etiology of autism is still unknown, but these ﬁndings suggest
that ASD phenotypes may be associated with metabolic
pathways imbalance. In order to explore this hypothesis,
metabolomics studies which have already shown their potential
in biomarker research in central nervous system disorders have
been performed.8
Metabolomics is the study of the metabolome, which
represents the whole content of low-molecular-weight com-
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pounds present in biological ﬂuids, cells, or tissues.9 Analytical
platforms most commonly used to identify and quantify
metabolites10−12 are mass spectrometry coupled to separation
techniques such as gas chromatography (GC−MS) or liquid
chromatography (LC−MS)13 and nuclear magnetic resonance
spectroscopy (NMR).
To date, few metabolomics studies have been described for
biomarkers exploration in ASD.14−17 These studies have been
primarily based on urine screenings, since urine can be obtained
in large quantities by noninvasive sampling. Moreover, repeated
sampling is easy to achieve, a major consideration in the case of
ASD children. These studies have been performed using a
single analytical platform, based on either NMR or MS
technologies. Although they have made the proof of concept
that exploration of the metabolome allows us to classify ASD
children compared to control, each analytical platform cannot
cover the whole diversity of metabolites in body ﬂuids
(molecular diversity and expression levels). Using a single
platform also results in partial information and diﬃculties in
conﬁrming identiﬁed metabolites as reliable biomarkers. In this
study, we take full advantage of NMR and MS complementarity
to explore the urine metabolome, using the combination of 1H
NMR, 1H−13C heteronuclear single quantum coherence
(HSQC) NMR, and liquid chromatography coupled to high-
resolution mass spectrometry (LC−HRMS). One of the
challenges of this approach is to associate data from diﬀerent
analytical platforms in order to generate a statistical model that
better represents urinary metabolic diﬀerences between
children with or without ASD. In order to achieve this, we
ﬁrst built independent supervised multivariate models for each
analytical modality in order to select the most discriminant
metabolites, which were then concatenated in a new single
matrix for a block-scaling model analysis. This multiplatform
approach, combined with data fusion, gave us the opportunity
to better classify children with or without ASD compared to a
unique analytical platform approach.
■ EXPERIMENTAL SECTION
Patients and Controls
Patients who met ASD diagnostic criteria according to the
World Health Organization’s International Statistical Classif ica-
tion of Diseases18 and the American Psychiatric Association’s
Diagnostic and Statistical Manual of Mental Disorders, 4th
edition,19 were included in the study after medical consultations
at the Regional Center for Autism in Tours, France, between
2011 and 2012. All parents of participants and participants
provided informed consent. Urine samples were collected from
30 children with ASD and 32 control children living in France.
The 62 patients urine samples (30 ASD and 32 controls)
were split into two sets: a training set of 46 samples (22 ASD
and 24 controls), and an independent validation set of 16
samples (8 ASD and 8 controls). Informations including sex,
diagnosis, gastrointestinal disturbances, and age at sampling
were collected for each participant. Urinary samples were
collected in sterile polypropylene tubes untreated with
preservatives. After centrifugation at high speed, each urine
sample was aliquoted in a 1.5 mL sterile Eppendorf tube and
stored at −80 °C immediately after collection until analysis.
NMR Study
Sample Preparation. Urine samples were thawed at room
temperature and centrifuged at 3000g for 10 min as described
previously.14,15 The supernatant (500 μL) was then added with
100 μL of phosphate buﬀer (pH = 7.4 ± 0.5) and 100 μL of
D2O solution for 1D analysis or 100 μL of D2O with internal
reference [3-trimethylsilylpropionic acid (TSP), 0.05 wt% in
D2O] for 2D analysis. Samples were then transferred into
conventional 5 mm NMR tubes for NMR analysis.
NMR Spectroscopy Experiments. 1H NMR spectra were
obtained as previously described using a Bruker DRX-500
spectrometer (Bruker SADIS, Wissembourg, France) operating
at 500 MHz, using a “cpmg” pulse program.
All sensitivity-enhanced 1H−13C HSQC spectra were
adapted from a previously described method on a Bruker
DPX Avance spectrometer operating at 300 MHz, using an
“hsqcgpphpr” pulse program in the Bruker library.
Data Preprocessing for NMR Analysis. Spectra were
processed using TopSpin version 2.1 software (Bruker
Daltonik, Karlsruhe, Germany), then aligned using the work
package “speaq” 20 in the R program. The aligned spectra were
then displayed in R, and zones with no peaks were removed
from the ﬁle. Finally, intensities of points corresponding to the
same peak or nearby peaks were added. These buckets
corresponded to either single metabolites or a range of
overlapped metabolites. The signal intensity in each bucket
was normalized by the total sum of peak intensities and
gathered in the 1H NMR matrix for further statistical analysis.
2D spectra were processed using MestReNova version 7.1.0
software (Mestrelab Research, S.L., Santiago De Compostela,
Spain) as previously described. Each urine spectrum was
normalized with an external reference TSP that served as a
chemical shift reference set at 0 ppm and as a quantitative
reference signal. The ﬁnal 2D matrix contained 677 diﬀerent
1H−13C cross-peaks between 10 and 150 ppm.
Peaks with low variability (relative standard deviation [RSD]
lower than 15%) were excluded from all data tables since they
would not be good predictive biomarkers.21
LC−HRMS Study
Sample Preparation. Samples were prepared from 20 μL
of urine, diluted at 1/10 in water or acetonitrile (ACN)
depending on the type of analytical column used (for HILIC or
C-18, respectively). After vortexing for 10 min and
centrifugation for 10 min at 10000g, 150 μL of the supernatant
was transferred into a 96-well plate. Quality controls samples
(QCs) were obtained from a pooled mixture of equal volumes
of all urine samples. QCs followed the same pre-analytic and
analytical steps described above. Fifteen QCs were injected to
equilibrate the chromatographic system before each analytic
batch. The running order of samples was randomized, and QCs
were analyzed every 10 samples.
Liquid Chromatography−High-Resolution Mass Spec-
trometry Analysis. MS Analysis. LC−HRMS analysis was
performed on a UPLC Ultimate 3000 system (Dionex),
coupled to a Q-Exactive mass spectrometer (Thermo Fisher
Scientiﬁc, Bremen, Germany) and operated in positive and
negative electrospray ionization (ESI+ and ESI−) modes (one
run for each mode). The system was controlled by Xcalibur 2.2
(Thermo Fisher Scientiﬁc). Four untargeted LC−HRMS
methods were conducted for better metabolome coverage:
C18 and HILIC chromatography coupled to ESI in both
positive and negative ion polarities. Each sample analysis
resulted in four separate data acquisitions. Chromatography was
carried out with a Phenomenex Kinetex 1.7 μm XB-C18 (150
mm × 2.10 mm) column with a Waters Cortecs 1.6 μm HILIC
(150 mm × 2.10 mm) column kept at 40 °C. For C18
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chromatography, a multistep gradient (followed by a 2 min
equilibration time) had a mobile phase A of 0.1% formic acid in
water, and a mobile phase B of ACN acidiﬁed with 0.1% formic
acid; the gradient operated at a ﬂow rate of 0.2 mL/min over a
run time of 30 min for both negative and positive modes.
The multisteps gradient was programmed as follows: 0−3
min, 0% B; 3−8 min, 0−15% B; 8−15 min, 15−50% B; 15−20
min, 50−100% B; 20−25 min, 100% B; 25−28 min, 100−0% B.
For HILIC chromatography, a multistep gradient (followed by
a 2 min equilibration time) had a mobile phase A of ammonium
formate in water (10 mM), and a mobile phase B with ACN
containing ammonium formate (10 mM); the ﬂow rate was 0.4
mL/min over a run of 22 min for both positive and negative
modes. The multisteps gradient was programmed as follows:
0−5 min, 0% A; 5−12 min, 0−20% A; 12−18.5 min, 20−60%
A; 18.5−19.5 min, 60% A; 19.5−20 min, 60−0% A. The
autosampler temperature (Ultimate WPS-3000 UHPLC
system, Dionex, Germany) was set at 4 °C, and the injection
volume for each sample was 5 μL for C18 and 10 μL for
HILIC.
Heated ESI source parameters were, for both modes, a spray
voltage of 3 kV, capillary temperature of 380 or 325 °C, heater
temperature of 350 or 325 °C, sheath gas ﬂow of 40 arbitrary
units (AU) or 35 AU, auxiliary gas ﬂow of 20 or 10 AU, spare
gas ﬂow of 2 or 1 AU, and tube lens voltage of 50 or 60 V for
C18 or HILIC, respectively. During the full-scan acquisition,
which ranged from 66.7 to 1000 m/z, the instrument operated
at 70 000 resolution (m/z = 200), with an automatic gain
control (AGC) target of 1 × 106 charges and a maximum
injection time (IT) of 250 ms.
MS2 Analysis of VIPs. First, a pool sample was injected for
molecular ion mass determination at a resolution of 140 000.
The most discriminant metabolites (variable importance
parameter, or VIPs) obtained from mass spectrometry were
then further investigated for their identiﬁcation. Targeted
tandem mass spectrometry (MS2) experiments were conducted
with an inclusion list of ions mass-selected from HILIC and
C18 analysis using an isolation window for the quadrupole of
0.5 m/z and a resolution of 35 000 (m/z = 200) for the
fragmentation spectrum, with an AGC target of 2 × 104
charges, a maximum IT of 100 ms, and a normalized energy
collision (Supporting Information, Figure S-3).
Data Preprocessing for LC−HRMS Analysis. XCMS
software22 implanted in the Galaxy platform (http://
workﬂow4metabolomics.org/the-galaxy-environment/) was
used to process raw data for peak alignment and framing.
This step produced a table of detected features, characterized
by sample retention time, m/z ratio, and intensity (i.e., peak
area). We normalized each peak area to the total peak area of
each chromatogram. For chromatograms obtained with HILIC
column in negative ionization mode, intensities of signals were
corrected with Loess23 after we observed an analytical deviation
of signals before normalization to total peak area.
The CAMERA package24 was used to group isotopes and
adducts in order to annotate and to identify features.
The stability of signals intensities across batches was
evaluated. Extracted ion chromatograms (EICs) were checked
in order to review consistency of integration across samples, to
analyze peak shapes, and to exclude background noise.
Variability of features passing this EIC quality review process
was then evaluated. QCs variability, given by RSD of each
feature, was assessed. Features with RSD in QCs higher than in
samples were excluded. We only kept features with RSD in
QCs below 30% for further multivariate analysis. Features
greater than 30% variance in QCs were not considered, except
if signiﬁcant variance was observed between groups, meaning
that biological variability may exceed analytical variability.25
Similarly to NMR experiments, we excluded peaks with RSD in
samples lower than 15%.
Data Processing
Multivariate Data Analysis. Quality Control Analysis for
LC−HRMS. Clustering of QCs was assessed by principal
component analysis (PCA) according to total peak area data
in order to compare analytical variability with biological
variability.
Samples Batch Data Analysis. The 62 patients samples (30
ASD and 32 controls) were split into two sets: a training set of
46 samples (22 ASD and 24 controls) for the identiﬁcation of
the most discriminants metabolites between ASD and control
urine samples, and an independent validation set of 16 samples
Figure 1. Workﬂow of treatment of data tables from NMR and LC−HRMS analysis.
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(8 ASD and 8 controls) to evaluate the performance of the
classiﬁcation models. This was accomplished by randomizing
samples. The training and independent validation sets were
matched by age and sex.
The general workﬂow for the training set is shown in Figure
1.
Each analytical method generated a data table with detected
features presented in columns and urine samples presented in
rows. The preprocessed data sets were used as input for Simca
P+ version 13.0 (Umetrics, Umea,̊ Sweden), and data analysis
was preceded by log transformation and unit variance scaling.
The training sets of these six data sets were tested individually
in order to ﬁnd the best orthogonal partial least-squares
discriminant analysis (OPLS-DA) model. Model development
was performed in order to (i) select a minimum set of
predictive metabolites (VIP > 1.0) that are the most implicated
in the diﬀerence between ASD and control urine samples and
(ii) test performance of the optimal model with receiver
operating characteristic (ROC) curve analysis and the
validation set data. The SIMCA prediction score (Ypred) on
the independent validation set was used to build the ROC
curves. The main beneﬁt of OPLS-DA compared to PLS-DA is
its ability to separate the systemic variation in variables X into
two parts: variation related to class membership to variation
unrelated to class membership (orthogonal). This partitioning
of the X-data will facilitate model interpretation and prediction
of new samples.26 OPLS-DA models performed on training set
were then evaluated by cross-validation by withholding 1/7 of
the samples in seven successive simulations, so that each sample
was omitted once in order to prevent against overﬁtting. The
set of multiple models resulting from cross-validation was used
to calculate jackknife uncertainty measures.27 We set a
maximum number of iterations at 200 in order to ensure
convergence of the OPLS algorithm.28 A Pearson correlation
test was performed between discriminant variables for each
analytical method to remove the redundancy of information
due to VIPs that correspond to the same metabolites. The
performance of each of the six OPLS-DA models was assessed
using a validation set data and ROC curves analysis.
A data fusion block-scaling model was then generated by
combining data tables coming from the previous six OPLS-DA
models. Block scaling, in the context of data fusion provides a
way to balance inﬂuence of blocks of variables in relation to
their size.29 Block scaling allows each group of variables to be
considered independently as an entity with a speciﬁc variance.30
This ﬁnal data fusion block-scaling OPLS-DA model was also
evaluated using a ROC curve analysis.
ROC curves were performed using GraphPad Prism version
6.00 for Windows (GraphPad Software, La Jolla, CA, USA,
http://www.graphpad.com/).
Univariate Data Analysis
Univariate analysis focused on the Variable Importance in
Projection (VIP > 1) obtained from the data fusion block-
scaling model using Wilcoxon test. A statistical correction for
multiple tests was applied in order to adjust the p-value for
signiﬁcance by accounting for the number of metabolites
evaluated (Bonferonni adjustment). So diﬀerences were
deemed signiﬁcant when p < 0.05/n (where n is the number
of VIPs). Statistical analyses were performed with JMP
statistical software version 7.0.2 (SAS Institute, Cary, NC,
USA).
Variable Importance Parameter Annotation
Most discriminant VIPs in multivariate analyses were
investigated to be annotated or identiﬁed. The VIP assignments
for molecular formula elucidation were made with the help of
seven golden rules in mass spectrometry.31 From the molecular
formula, free access databases queries using ChemSpider
(http://www.chemspider.com/), Human Metabolome Data-
base (http://www.hmdb.ca/), and MassBank (http://www.
massbank.jp/) were used to annotate compounds. Finally, each
VIP was analyzed at high resolution and by MS2. From HRMS
(ion mass and isotopic abundances), one or several parent
structures are generated. To determine the structure of these
compounds, Mass Frontier software’s fragment comparator
(Thermo Scientiﬁc) gives the opportunity to compare
fragments derived from diﬀerent compounds. First, Mass
Frontier software predicted comprehensive pathways based
on a set of general ionization, fragmentation, and rearrange-
ment rules. Fragmentation spectra were then compared to ab
initio fragmentation spectra of potential identiﬁed metabolites
using Mass Frontier.32 Experimental MS2 mass spectra with
fragment structure annotations are given in the Supporting
Information (Figure S-3, which illustrates this compound
annotation workﬂow).
For VIPs obtained from 2D NMR (1H−13C HSQC),
chemical shifts were submitted to the MetaboMiner database
(http://wishart.biology.ualberta.ca/metabominer/). In Me-
taboMiner, a compound is considered to be present if the
requirements of minimal signatures are met. A minimal
Table 1. ASD and Control Groups’ Characteristics
training set independent validation set
ASD (n = 22) control (n = 24) ASD (n = 8) control (n = 8)
age, yearsa 8.64 ± 3.62 8.08 ± 3.67 9.24 ± 3.79 9.37 ± 4.07
no. of males (%)a 19 (86.36%) 21 (87.50%) 7 (87.50%) 6 (75%)
no. of females (%)a 3 (13.64%) 3 (12.50%) 1 (12.50%) 2 (25%)
diagnostic
autism disorder 9 0 2 0
Asperger’s syndrome 2 0 0 0
PDD-NOS 11 0 6 0
neurotypical 0 24 0 8
gastrointestinal disturbance
yes 9 NA 5 NA
no 12 NA 3 NA
NA 1 24 0 8
aData are expressed as mean.
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signature is deﬁned as the minimum peak set of that can
uniquely identify a compound from all others in a given spectral
library.33 A compound is considered potentially identiﬁed when
a minimal signature is highlighted.
For VIPs obtained from 1H NMR, we used the Chenomx
database (http://www.chenomx.com/). These queries resulted
in metabolites propositions that were considered for identi-
ﬁcation if all chemical shifts of theoretical spectra matched our
experimental spectra. Chemical shifts of NMR VIPs are given in
the Supporting Information (Table S-1).
■ RESULTS AND DISCUSSION
The 62 patient urine samples (30 ASD and 32 controls) were
split into two sets: a training set of 46 samples (22 ASD [mean
8.64 years] and 24 controls [mean 8.08 years]), and an
independent validation set of 16 samples (8 ASD [mean 9.24
years] and 8 controls [mean 9.37 years]). Information collected
for each participant, including age, sex, age at diagnosis,
medication, and age at sampling, is summarized in Table 1.
Diﬀerences of age and sex between groups of training sets are
not signiﬁcant (p-value = 0.52 for age and p-value = 1 for sex)
likewise for validation set (p-value = 0.73 for age and p-value =
1 for sex).
NMR Experiments
1H NMR. 1H NMR spectroscopy, a rapid, robust, and reliable
analytical tool with high reproducibility, has shown its potential
to explore the urine metabolome in ASD patients.34,35
1H NMR spectra (0−9.5 ppm) were divided in 147 buckets.
After removing buckets with low variability in patients (RSD <
15%), the data table of the training set (138 buckets) was
analyzed by OPLS-DA. Performances of OPLS-DA internal
cross-validated model obtained with 8 discriminant variables,
were R2Y(cum) = 0.52, Q2 = 0.37 (Table 2). The sensitivity
(percentage of ASD children correctly identiﬁed) obtained
from the OPLS-DA model using the training set was 81.8%,
and speciﬁcity (percentage of healthy children correctly
identiﬁed) was 91.7%. OPLS-DA model p-value was signiﬁcant
(p-value = 6 × 10−4). This OPLS-DA model was then
externally evaluated using the independent validation set and
ROC curve analysis. Area under curve (AUC) was 0.83, and p-
value was 0.03 (Supporting Information, Figure S-2). The
sensitivity and speciﬁcity obtained from the ROC curve analysis
using the independent validation set were lower, with respective
values of 62.5% and 87.5% (Table 2). This result shows that the
internal validation during OPLS-DA model construction
overvalued prediction’s capacity due to overﬁtting of data.
Assessing classiﬁcation performances of each model by an
independent set appears to be necessary in order to minimize
this overvaluation.
1H−13C NMR. 1H NMR signals can be disturbed by spectral
overlap, resulting in a potential lack in spectral resolution and
making diﬃcult the identiﬁcation step. To improve the
resolution of urine components, a two-dimensional NMR
(1H−13C HSQC NMR) acquisition may be valuable. 1H−13C
HSQC-based NMR avoids spectral overlap by dispatching the
overall information in two dimensions. Compared to the data
table of 138 buckets of 1H NMR, the 1H−13C HSQC NMR list
containing 677 diﬀerent 1H−13C cross-peaks between 10 and
150 ppm was established as previously described due to less
overlap of the signals.
The model obtained by 1H−13C HSQC NMR gave a better
information on prediction with a Q2 = 0.51 (Table 2) obtained
from 7 cross peaks in the optimized OPLS-DA model
compared to 1H NMR OPLS-DA model (Q2 = 0.37). The
OPLS-DA model sensitivity for the training set was found
higher compared to the 1H NMR (86.36% vs 81.82%).
However, speciﬁcity was found lower compared to the 1H
NMR (75% vs 91.7%). The p-value of the 1H−13C HSQC
NMR OPLS-DA model was signiﬁcant (p-value = 2 × 10−7).
Regarding the validation set, AUC ROC curve gives results
similar to those obtained with 1H NMR (0.84 vs 0.83), and the
p-value of the 1H−13C HSQC NMR ROC curve was 0.03.
The sensitivity of ROC curve analysis for independent
validation was found better compared to the 1H NMR (75% vs
62.5%) with an equal speciﬁcity between them (87.5%). There
again, these results show that overﬁtting of data in OPLS-DA
models could be attenuated by the use of a validation set, and a
better spectral separation results in a better sensitivity in
discriminant analysis.
LC−HRMS Analysis
Since only a few untargeted metabolomics studies by LC−MS
have been realized with urines of ASD patients, and since they
have been done using a single chromatographic column type
(C18),36 we decided, in order to better cover the urine
metabolome, to analyze each sample using LC−HRMS coupled
to a HILIC or C18 column in both positive (ESI+) and
negative (ESI−) ionization modes. Four independent models
were built depending on column separation and ionization
mode.
Table 2. Summary of Statistical Values of OPLS-DA Models and ROC Curve Analysis of Training Set and Independent
Validation Set Obtained with the Diﬀerent Methodologiesa











1H NMR 8 0.52 0.37 81.8 91.7 6 × 10−4 0.83 0.02 62.5 87.5
1H−13C NMR 7 0.59 0.51 86.4 75.0 2 × 10−7 0.84 0.03 75.0 87.5
HILIC ESI+ 9 0.51 0.47 86.4 91.7 1 × 10−6 0.70 0.17 100 62.5
HILIC ESI− 4 0.40 0.34 77.3 79.2 1 × 10−3 0.64 0.34 62.5 75.0
C18 ESI+ 7 0.64 0.53 90.9 91.7 3 × 10−6 0.78 0.06 62.5 87.5
C18 ESI− 11 0.48 0.39 86.4 75.0 2 × 10−5 0.83 0.03 87.5 75.0
block model 46 0.88 0.75 100 100 9 × 10−12 0.91 0.006 100 75.0
aThe diﬀerent cumulative modeled variations in Y matrices [R2Y(cum)] on spectral datasets and predictability of the model (Q2) are given
[observations (N) = 46]. bSensitivity = the number of diseased subjects that are correctly identiﬁed as diseased. cSpeciﬁcity = the number of healthy
subjects that are correctly identiﬁed as healthy in the training set and validation set. dp-value of ROC curve analysis.
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Quality Control
Fifteen QCs were injected to equilibrate the chromatographic
system before each analytical batch.
PCA scatter plots of QCs and samples were analyzed in
order to compare analytical and biological variabilities for each
batch. As shown in Figure S-1 in the Supporting Information,
the clustering of QCs compared to samples clearly shows that
biological variability exceeds the analytical one. This QCs step
validates all batches series.
HILIC Analysis
HILIC provides a good separation for polar metabolites that are
of major abundance in urine. This is the ﬁrst study performed
with HILIC chromatography in order to explore ASD urine
metabolome. After data preprocessing (see above), data tables
contained 1067 and 845 features in ESI+ and ESI−.
Multivariate analysis gave the similar ability to separate the
two populations of urine samples with slightly better statistical
values (R2Y(cum) = 0.51 and Q2 = 0.47) for ESI+ compared to
ESI− (R2Y(cum) = 0.4 and Q2 = 0.34).
The OPLS-DA models’ sensitivities (built with 9 and 4
variables from ESI+ and ESI−, respectively) were 86.4% and
77.3% for ESI+ and ESI−, respectively. Likewise, the OPLS-DA
models’ speciﬁcities were 91.7% and 79.2% for of ESI+ and
ESI−, respectively. AUCs curves for the validation set (ESI+
and ESI−, respectively) were 0.70 and 0.64 (Supporting
Information, Figure S-2). Model curves were not found to be
signiﬁcant (p > 0.05), unlike p-values of OPLS-DA models that
were signiﬁcant (Table 2). Reasons for these discrepancies
could be an overﬁtting of the OPLS-DA models and/or too
small a number of samples for the validation set.
C18 Analysis
Reverse-phase separations are ideal for relatively nonpolar
metabolites. A total of 1555 and 1226 features in ESI+ and
ESI−, respectively, were selected as repeatable. From C18 ESI−
data, an OPLS-DA model built with 11 discriminant variables
gave statistical parameters R2Y(cum) = 0.48 and Q2 = 0.39
(Table 2). The sensitivity and speciﬁcity of this OPLS-DA
model were 86.36% and 75%, respectively, with a signiﬁcant p-
value = 2 × 10−5. The performance of this model was also
evaluated using the ROC curve, and we found sensitivity and
speciﬁcity similar to those of the OPLS-DA model (Table 2).
AUC was found to be 0.83, with a signiﬁcant p-value = 0.03
(Supporting Information, Figure S-2). The signiﬁcant p-value of
ROC curve conﬁrms here that the OPLS-DA model is able to
classify ASD patients and controls with minimum overﬁtting.
The OPLS-DA model obtained with 9 discriminant variables
from C18-ESI+ data gave better information on the class
descriptor, with R2Y(cum) = 0.64. Moreover, compared to
other LC−HRMS modalities, ESI+ model gave the highest
predictive ability, with Q2 = 0.53 and p-value = 3 × 10−6. OPLS-
DA model sensitivity and speciﬁcity were 90.9% and 91.7%,
respectively. Despite these models results, the ROC curve’s
AUC value was not found to be signiﬁcant (p-value = 0.06).
Multivariate Statistical Analysis of the Combined 1H NMR,
1H−13C HSQC NMR, ESI+/− C18 Column, and ESI+/− HILIC
Column
The fusion and extraction of information from multiple data
tables has become a decisive issue.37 Several strategies can be
used to associate data from diﬀerent analytical platforms. The
simplest approach is to concatenate the diﬀerent data sets in a
low-level fusion approach where the data matrix results in a
fused data table that is used for multivariate analysis.38 This
approach is greatly aﬀected by disparate signal intensities in the
range and size of the data matrix obtained from the diﬀerent
analytical platforms. In order to address this issue, the selection
of the most relevant/predictive variables from each data tables
may solve the problem of dimensionality. Such strategies are
called intermediate or midlevel data fusion.39 The model
responses are combined in order to produce a ﬁnal “fused”
response that provides a meaningful synthesis. Following a
midlevel data fusion strategy, the most discriminant variables of
each analytical platform (1H NMR, 1H−13C HSQC, C18 ESI
+/−, and HILIC ESI+/−) were selected and combined in
order to build a data fusion block-scaling model. Since a subset
of the most valuable variables can be selected from each data
sources, the prediction performance can be increased when
compared with individual analysis. While some signals are
expected to be common to diﬀerent blocks, the remainder
would be speciﬁc and should give complementary information.
Since a data fusion model could be dominated by the largest
matrices for numerical reasons, the fairness between blocks was
ensured by unit variance scaling normalization.
We ﬁrst built six independent OPLS-DA models in order to
select the most discriminant variable (VIP > 1.0) for each
analytical platforms: 8, 7, 7, 11, 9, and 4 variables from 1H
NMR, 1H−13C HSQC, C18 ESI+, C18 ESI−, HILIC ESI+, and
HILIC ESI−, respectively. An equal weight was then assigned
to each block corresponding to each analytical platform in the
data table.
The data fusion block-scaling model was obtained from 46
features giving performances parameters R2Y(cum) = 0.88, Q2
Figure 2. OPLS-DA model and ROC curve analysis obtained from training set and independent validation set. (a) Data fusion block-scaling of
OPLS-DA model on training set [R2Y(cum) = 0.88, Q2 = 0.75, p = 9 × 10−12]. (b) ROC curve analysis of independent validation set (8 ASD and 8
controls).
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= 0.75, p-value = 9 × 10−12, and 100% speciﬁcity and sensibility
(Table 2, Figure 2).
When we performed the ROC curve analysis, an AUC of
0.91 was obtained, with a signiﬁcant p-value of 0.006 (Table 2,
Figure 2). In addition, sensitivity was found to be improved
when compared to each separate analytical platform.
Besides its classiﬁcation capacities, OPLS-DA model gives
the opportunity to highlight metabolites that are the most
involved with this classiﬁcation.
Table 3 shows the most discriminant metabolites (VIP > 1),
their variations in the ASD group, and the associated univariate
p-value.
First, we found higher levels of N-acetylarginine in the ASD
group compared to controls. Arginine has been described to be
higher in plasma samples of ASD children.40 Excessive arginine
is thought to induce oxidative stress via NO production.41 We
also found perturbations of guanidinosuccinic acid and
methylguanidine, which are produced from oxidation of
argininosuccinic acid and creatine, respectively, by free
radicals.42,43 The exact relationship between arginine pathway
and oxidative stress in neuropsychiatric disorders remains
unclear; however, a common susceptibility gene for ASD and
schizophrenia, NOS1, has been suggested to be involved in the
arginine-NO pathway.44,45 This metabolic proﬁle is consistent
with impaired oxidative stress in children with autism.46 The
exact relationship between the guanidino compounds pathway
and autism needs further investigation.
Dihydroxy-1H-indole glucuronide I and desaminotyrosine,
which are related to tyrosine metabolism, were also found in
the most discriminant metabolites. These results, associated
with perturbations in the levels of valine47,48 and N-
acetylasparagine, are in agreement with perturbations of
amino acids levels published by Tu et al.48 and may be
interpreted as abnormal amino acids metabolism aﬀecting
neurotransmitters levels such as dopamine, noradrenaline, and
epinephrine as observed in ASD children.48
Level of dihydrouracil, an intermediate breakdown product
of uracil, was found altered in ASD children’s metabotypes.
Purines and pyrimidines disorders, such as dihydropyrimidine
dehydrogenase or dihydropyrimidinase deﬁciencies and ad-
enylosuccinate lyase or adenosine deaminase deﬁciencies, have
been linked to autistic features.
Deﬁciencies of dihydropyrimidine dehydrogenase, the
enzyme which catalyzes the conversion of uracil to dihydrour-
acil, have been linked to ASD. Indeed, symptoms of this
pyrimidine disorder include psychomotor retardation, epileptic
encephalopathy, and autistic features.
Recent studies have shown that an antipurinergic therapy
could reverse the behavioral and metabolic disturbances in the
maternal immune activation mouse model49,50 and in the
Fragile X (Fmr1 knockout) mouse model. From these two
mechanically distinct examples of ASD mouse models, the
purinergic pathway is a neurochemical hypothesis that triggers
the evolutionarily conserved cell danger to stress that may be
associated with ASD.
Indoxyl and indoxyl sulfate, which are produced by
tryptophan metabolism in gut bacteria, were found here as
metabolite candidates (from diﬀerent analytical modality: NMR
1D and 2D and HILIC ESI+) and conﬁrmed our previous
results.14 Since indoxyl sulfate has been found as a VIP in more
than one analytical platform, it may be assumed that this
metabolite expression is modiﬁed between our two groups of
children.
Desaminotyrosine, which can also be the result of
deamination of tyrosine by intestinal microﬂora,51,52 was
found increased in the ASD group. Moreover, a recent study
by Noto et al. using GC/MS as an analytical platform points
out a gut microbiota dysfunction, including tyrosine metabo-
lism perturbation.53 Our study also points out perturbations of
phenylacetylglutamine (PAG) and p-cresol sulfate concen-
trations, which are also produced by the microbiota respectively
from tyrosine54 and phenylalanine.55 These results which
conﬁrmed those previously reported15,55 underline the
importance of mammalian-microbial cometabolites in
ASD,16,17,53 supporting emerging evidence for a gut-brain
connection in autism, wherein gastrointestinal microbiota may
contribute to the ASD symptoms.56 It has to be noticed that
half of our autistic cohort is clinically diagnosed as suﬀering of
gastrointestinal disturbances that include diarrhea, constipation,
and colitis.
Whether it is the cause or the consequence of autism’s
physiopathology, our results conﬁrm that gut microbiome
seems to be associated with this disorder.
It has been recently shown that there are gender diﬀerences
in emotions and sociability in children with autism spectrum
disorders.57 This suggests that, in addition to phenotypic
diﬀerences, there are metabotype diﬀerences linked to gender.
One should keep in mind that the statistical power of our study
is related to the small size of our groups of patients (training
and control sets), emphasized by the small number of patients
Table 3. Putatively Annotated Metabolites of Data Fusion
OPLS-DA Model (VIP > 1)
analytical












guanidinosuccinic acid 0.007 ↓









p-cresol sulfate 0.02 ↑
NMR 1D indoxyl sulfate 0.01 ↑
methylguanidine 0.003c ↓
NMR 2D valine 0.06 ↑
indoxyl sulfate 0.003c ↑
glucuronic acid 0.009 ↑
ap-value of univariate analysis (Wilcoxon test). b↑ denotes higher level
in ASD urines, ↓ denotes lower level in ASD urines. cSigniﬁcant p-
value after Bonferroni correction (p < 0.003).
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enrolled. Since only a few females have been included in this
study, this tends to decrease the biological signiﬁcance of our
conclusions. However, signiﬁcant metabolic diﬀerences found
in this work between ASD and control children may underline a
typical general metabolic signature of ASD.
■ CONCLUSION
The discovery of biomarkers for an early diagnosis of ASD, as
well as a follow-up of its evolution for improved patient care, is
still a challenge to achieve. Because of its noninvasive
accessibility and since it has already shown potential for
containing discriminative metabolites, we decided to explore
the metabolome of children’s urine as deeply as possible, using
six complementary analytical platforms: 1H NMR, 1H−13C
NMR, and ESI+ and ESI− LC−MS with C18 and HILIC
chromatographic support.
First, our results highlighted and conﬁrmed that several
metabolic pathways associated with amino acids, including
tyrosine, asparagine, phenylalanine, tryptophan, and arginine,
seem to be involved in ASD. In addition, as other studies have
previously shown, a gut dysbiosys is likely to be associated with
ASD. It is important to notice that all these metabolism
perturbations could be observed in a single study, thanks to the
use of a multiplatform strategy that enabled a deep exploration
of the metabolome. Second, our results showed that OPLS-DA
model construction based on data fusion and block scaling by
combining the most discriminant variables from multiple
analytical methods results in a valuable model for prediction.
Using the complementarity of analytical methods associated
with the selection of the most relevant variables, our OPLS-DA
model has raised the predictive power, with an AUC of 91% in
the validation set, which conﬁrms the promise of combining
multiple analytical methods by multivariate analyses.
Our results need to be validated within a larger cohort of
patients, ﬁrst in order to conﬁrm this metabolites panel as a
potential clinical tool, but also in order to explore the
metabotype variability associated with ASD phenotype’s
heterogeneity, especially when considering gender.
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